Article Sidebar

Submitted
Jun 8, 2021
Published
Jun 8, 2021
Download
PDF
Statistic
Read Counter : 78 Download : 72

Main Article Content

Abstract

Neurodegeneration refers to a condition of neuronal death occurring as a result of progressive disease of long-term and is becoming a major health problem in the 21st century. Neurons degenerated are not replaced resulting in a cognitive loss, many neurodegenerative disorders, such as schizophrenia, depression, Alzheimer's disease (AD), dementia, cerebrovascular impairment, seizure disorders, head injury, parkinsonism. AMP-activated protein kinase (AMPK) boosts SIRT activation by increasing cellular NAD+ levels, which leads to deacetylation and regulation of downstream SIRT1 targets including peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1) (16), a master regulator of mitochondrial biogenesis Thus the herbal plants can be a valuable source of the drug against neurodegenerative disorders which will require high-throughput screening. Glutamate receptor-mediated excitotoxicity has been associated with several diseases of the brain, whereas in vivo and in vitro studies have shown that blocking the NMDA and the non-NMDA receptors simultaneously results in maximum protection against ischemic neurodegeneration. This review will highlight the role of herbal plants and their phytoconstituents against neurodegenerative diseases and other related disorders, focusing on their mechanism of action and therapeutic potential.

Keywords

Apoptosis Herbal medicine Neurodegenerative diseases Neuroprotective

Article Details

How to Cite
Syed Iqra Naznin, Tarif hussain, Govind pawar, & Rahul Amin. (2021). Review on some indigenous herbals for neuroprotective effect. International Journal of Research in Pharmacology & Pharmacotherapeutics, 10(2), 118-124. https://doi.org/10.61096/ijrpp.v10.iss2.2021.118-124
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. 1. Kochupilai N 2000, Clinical Endocrinology in India. Current Sci. 79: 1061-7.
  2. 2. King H, Aubert RE, Herman WH. Global burden of diabetes 1995-2025: Prevalence, numerical estimates and projection. Diabetes Care. 1998, 21: 1414-31.
  3. 3. Boulton, A. J., Vinik, A. I., Arezzo, J. C., Bril, V., Feldman, E. L., Freeman, R. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005, 28(4),956−962.
  4. 4. Vinik A, Mehrabyan A. Diabetic neuropathies. A complete review of the diagnosis and treatment of diabetic neuropathy. Med Clin North Am. 2004, 88:947–999.
  5. 5. Obrosova I.G 2009, “Diabetic Painful and Insensate Neuropathy: pathogenesis and Potential treatments,” Neurotherapeutics. vol. 6, no. 4, pp. 638–647.
  6. 6. Greene, D.A., M.J. Stevens, I. Obrosova and E.L. Feldman. Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy. Eur. J. Pharmacol. 1999, 375:217-223.
  7. 7. Patel, K., Srinivasan, K. Plant foods in the management of diabetes mellitus: vegetables as potential hypoglycemic agents. Nahrung. 1997, 41:68–74.
  8. 8. Kar, A, Choudhary BK and Bandyopadhyay NG, comparative evaluation of hypoglycemic activity of some Indian medicinal plants in alloxan diabetic rats, J Ethnopharmacol. 2003,84(1):105-108
  9. 9. Frankish N, de Souza Menezes F, Mills C, Sheridan H, Enhancement of Insulin Release from the ß- Cell Line INS-1 by an Ethanolic extract of Buahiniavariegata and Its Major Constituent Roseoside, Planta Med. 2010,76:995-997.
  10. 10. Swain LE, Downum KR, Light-activated toxins of the Moraceae. Biochem. Sys. Ecol. 1990, 18:153-156.
  11. 11. Mishra A, Kumar S, Bhargava A, Sharma B, Pandey AK, Studies on in vitro antioxidant and antistaphylococcal activities of some important medicinal plants, Cellular and Molecular Biology. 2011, 57(1):16-25.
  12. 12. Zhao Y., Ye W., Boye K.S., Holcombe J.H., Hall J.A., Swindle R. Prevalence of other diabetes associated complications and comorbidities and its impact on health care charges among patients with diabetic neuropathy, J. Diabetes Its Complicat. 2008.
  13. 13. Taylor V.H., MacQueen G.M. Cognitive dysfunction associated with metabolic syndrome, Obes. Rev. 2007,8:409–418
  14. 14. Biessels GJ, Kappelle AC, Bravenboer B, Erkelens DW, Gispen WH. Cerebral function in diabetes mellitus. Diabetologia. 1994, 37:643–50.
  15. 15. Singh, N., Armstrong, D. G., & Lipsky, B. A. Preventing foot ulcers in patients with diabetes. Jama. 2005,293(2):217−228.
  16. 16. Simmons, Z., Feldman, E. L., Williams, R., Herman, W., Kinmonth, A. L., & Wareham, N. J. Treatment of diabetic neuropathy. The Evidence Base for Diabetes Care. 2002,555−576.
  17. 17. Wernicke, JF, Pritchett, YL, D'Souza, DN, Waninger, A, Tran, P, Iyengar, S. A Randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006, 67:1411−1420.
  18. 18. Kochar, D. K., Rawat, N., Agrawal, R. P., Vyas, A., Beniwal, R.,Kochar,
  19. 19. S. K. Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo- controlled study. Qjm. 2004, 97(1),33−38.
  20. 20. Dallocchio, C., Buffa, C., Mazzarello, P., &Chiroli, S. Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain SympManag. 2000, 20(4)280−285.
  21. 21. Dworkin, RH., O'Connor, AB., Backonja, M., Farrar, JT., Finnerup, NB., Jensen, TS.Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007b, 132(3),237−251.
  22. 22. The Capsaicin Study, G. 1992, Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Diabetes Care 15, 159−165.
  23. 23. Barbano, R. L., Herrmann, D. N., Hart-Gouleau, S., Pennella-Vaughan, J., Lodewick, P. A., Dworkin, R. H. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol. 2004, 61(6),914−918.